Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

NCT ID: NCT02149823

Last Updated: 2022-10-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 92 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-09-30
• Study Completion Date: 2022-06-14

Brief Summary

Social cognition impairment is critical to the pathology and morbidity of a number of psychiatric disorders, including the schizophrenia spectrum, the autism spectrum and the personality disorders, thus representing a dimension consistent with RDoC. As such, this study aims to a) further characterize the unique deficits in social cognition (recognition and interpretation of social cues and representation of thoughts, intentions, and feelings of others) across disorders, including the schizophrenia spectrum (which includes schizophrenia, SCZ, schizoaffective disorder, SAD, bipolar disorder, BD, and schizotypal personality disorder, SPD), the autism spectrum disorders (ASD), and borderline personality disorder (BPD) compared to healthy controls (HC); b) assess the effect of intranasal oxytocin (OXT) as a regulator and novel treatment of social cognition impairment in these disorders; and c) enhance our understanding of the specificity and exact mechanisms of impairment to inform the accurate dosing of OXT required to modulate social cognition in these disorders and identify a model of optimum social cognitive function. Addressing these questions will further catalyze research into a model of optimum social cognitive activity, and accelerate industry development of agents suited to routine clinical administration.

Detailed Description

Social cognitive impairments, particularly deficits and distortions in recognition and interpretation of social cues and representations of thoughts, intentions, and feelings of others-termed mentalization-are a key contributor to the pathology and morbidity of a number of psychiatric disorders, including the schizophrenia spectrum, the autism spectrum and personality disorders. Individuals with schizophrenia spectrum disorders have deficits in social cognition (hypomentalization), while individuals with borderline personality disorder seem to have exaggerated and distorted social cognition (hypermentalization). However, the specificity and mechanisms of these impairments remain unclear. Therefore, a better understanding of the modulation of social cognition is a priority for developing interventions both pharmacologic and psychosocial. We propose here to examine the effects of oxytocin, known to be a key regulator of social cognition through modulating frontolimbic neural circuitry, on social cognition in schizotypal and borderline patients. In doing so, we aim to characterize a model of optimum social cognitive activity to direct the development of treatments, including dosing and target population-specific effects.

To this end, we propose to perform a 2-year study in which 105 patients, (45 with schizophrenia spectrum disorders, 30 with borderline personality disorder, and 30 with autism spectrum disorders) will perform 3 rounds of social cognition testing after three acute single-dose treatment conditions (intranasal oxytocin dose of 24IU or 40IU or placebo) separated by a washout period, in a repeated-measures, within-subjects, randomized, placebo-controlled, double-blind, counterbalanced cross-over proof-of concept design. 30 healthy controls will not receive oxytocin/placebo and will perform 3 rounds of social cognition tests separated by approximately 4 weeks, serving as a benchmark for normal performance and a control for practice effects. Social cognitive testing will be performed 45 minutes after drug/placebo administration in an identical protocol each time. The social cognitive test serving as primary outcome measure will be the Movie for the Assessment of Social Cognition (MASC). We will also include other tests of social cognition and symptom measures, to evaluate scope of effects. We will compare outcome measures at baseline (placebo day) in schizotypal and borderline patients and healthy controls, and in schizotypal and borderline patients across drug doses and placebo administration.

Furthermore, 60 subjects (15 HC, 15 with schizophrenia spectrum disorders, 15 BPD, and 15 with autism spectrum disorders, either new subjects or already enrolled subjects) will be expected to complete an add-on MRI component of the study, after signing an additional consent form. For the MRI portion of the study, these subjects will perform 2 more rounds of social cognition testing after receiving double-blind intranasal oxytocin (40 IU) or placebo in randomized order, in a cross-over, within-subjects design, separated by approximately a 1-week washout. The subjects will receive the study medication directly prior to beginning an fMRI scan that will last approximately two hours. Oxytocin levels will be measured before oxytocin administration and every 10-15 minutes until about 2 hours and 30 minutes post-administration. The remainder of the protocol will remain the same.

Conditions

Borderline Personality Disorder; BPD; Schizotypal Personality Disorder; SPD; Autism Spectrum Disorder; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Intranasal Oxytocin Group 1

Placebo on visit 1, oxytocin 24IU on visit 2, then 40 IU on visit 3

Group Type: ACTIVE_COMPARATOR

Syntocinon 24 Intranasal Units (IU)

Intervention Type: DRUG

Syntocinon 40 Intranasal Units (IU)

Intervention Type: DRUG

Intranasal Placebo

Intervention Type: DRUG

Intranasal Oxytocin Group 2

oxytocin 24IU on visit 1, placebo on visit 2, then oxytocin 40IU on visit 3

Group Type: ACTIVE_COMPARATOR

Syntocinon 24 Intranasal Units (IU)

Intervention Type: DRUG

Syntocinon 40 Intranasal Units (IU)

Intervention Type: DRUG

Intranasal Placebo

Intervention Type: DRUG

Intranasal Oxytocin Group 3

oxytocin 40IU on visit 1, oxytocin 24IU on visit 2, then placebo on visit 3.

Group Type: ACTIVE_COMPARATOR

Syntocinon 24 Intranasal Units (IU)

Intervention Type: DRUG

Syntocinon 40 Intranasal Units (IU)

Intervention Type: DRUG

Intranasal Placebo

Intervention Type: DRUG

Intranasal Oxytocin Group 4

after visit 4, placebo on subsequent visit , then oxytocin 40IU at following visit

Group Type: ACTIVE_COMPARATOR

Syntocinon 40 Intranasal Units (IU)

Intervention Type: DRUG

Intranasal Placebo

Intervention Type: DRUG

Intranasal Oxytocin Group 5

after visit 4, oxytocin 40IU on subsequent visit, then placebo at following visit

Group Type: ACTIVE_COMPARATOR

Syntocinon 40 Intranasal Units (IU)

Intervention Type: DRUG

Intranasal Placebo

Intervention Type: DRUG

Interventions

Syntocinon 24 Intranasal Units (IU)

Intervention Type: DRUG

Syntocinon 40 Intranasal Units (IU)

Intervention Type: DRUG

Intranasal Placebo

Intervention Type: DRUG

Other Intervention Names

Intranasal Oxytocin; Intranasal Oxytocin

Eligibility Criteria

Inclusion Criteria

• 18 ≤ age ≤ 65
• Medically and neurologically healthy
• Willing and able to provide informed consent
• IQ≥80

Exclusion Criteria

• Currently meets for a psychotic episode
• Clinically significant cardiovascular or neurological conditions, traumatic brain injury, uncontrolled hypertension, clinically significant EKG abnormalities, or serious general medical illness
• Clinical evidence of dehydration or significant hypotension; pregnant or lactating
• Currently meets DSM-IV-TR criteria for MDD
• Current substance abuse (last 6 months) or past dependence on stimulants, opioids or other potentially neurotoxic drugs
• Currently taking psychotropic or other systemic medications
• Non-English speaking

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

James J. Peters Veterans Affairs Medical Center

FED

Sponsor Role: collaborator

VISN 3 Mental Illness Research, Education and Clinical Center

FED

Sponsor Role: collaborator

Maria de las Mercedes Perez Rodriguez

OTHER

Sponsor Role: lead

Responsible Party

Maria de las Mercedes Perez Rodriguez

Fellow

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Maria de las Mercedes Perez Rodriguez, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai; James J. Peters VA Medical Center

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, United States

James J Peters VA Medical Center

The Bronx, New York, United States

Countries

United States

Other Identifiers

UL1TR000067

Identifier Type: NIH

Identifier Source: secondary_id

View Link

GCO 13-0340

Identifier Type: -

Identifier Source: org_study_id